Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda

Nicholas Musinguzi, Rain A. Mocello, Yap Boum, Peter W. Hunt, Jeffrey N. Martin, Jessica E. Haberer, David Bangsberg, Mark J. Siedner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Little is known about associations between viral suppression, adherence, and duration of prior viral suppression in sub-Saharan Africa. Study participants were from the UARTO study in Mbarara, Uganda. We fit regression models to characterize relationships between average adherence, treatment interruptions, and rebound viremia (>400 copies/mL) following a previously undetectable result. Our goal was to understand the impact of prior viral suppression on these relationships. 396 participants contributed 2864 quarterly visits. Restricted to periods with average adherence <50 %, each 10 % increase in adherence reduced the odds of rebound viremia by 74 % [adjusted odds ratio (AOR) = 0.26, P = 0.002] and 29 % (AOR = 0.71, P = 0.057) during the first 12 months of suppression and beyond 12 months respectively, interaction term P = 0.018. Among periods with adherence ≥50 %, the risk of rebound viremia decreased with increasing adherence during the first 12 months of viral suppression (AOR = 0.73 for each 10 % increase, P = 0.001), but not thereafter (AOR = 1.09, P = 0.67), interaction term P = 0.027. In contrast, 72-h interruptions, were associated with increased rebound viremia during the first 12 months (AOR = 1.30, P = 0.009) and after (AOR = 1.39, P = 0.005), interaction term P = 0.69. Completing 12 months of viral suppression decreases the impact of average adherence, but not prolonged treatment interruptions, on risk of rebound viremia.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalAIDS and Behavior
DOIs
StateAccepted/In press - Jun 2 2016
Externally publishedYes

Fingerprint

Uganda
Viremia
Odds Ratio
Therapeutics
Africa South of the Sahara

Keywords

  • Adherence
  • ART
  • Suppression
  • Viremia

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Social Psychology

Cite this

Musinguzi, N., Mocello, R. A., Boum, Y., Hunt, P. W., Martin, J. N., Haberer, J. E., ... Siedner, M. J. (Accepted/In press). Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda. AIDS and Behavior, 1-6. https://doi.org/10.1007/s10461-016-1447-1

Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda. / Musinguzi, Nicholas; Mocello, Rain A.; Boum, Yap; Hunt, Peter W.; Martin, Jeffrey N.; Haberer, Jessica E.; Bangsberg, David; Siedner, Mark J.

In: AIDS and Behavior, 02.06.2016, p. 1-6.

Research output: Contribution to journalArticle

Musinguzi, Nicholas ; Mocello, Rain A. ; Boum, Yap ; Hunt, Peter W. ; Martin, Jeffrey N. ; Haberer, Jessica E. ; Bangsberg, David ; Siedner, Mark J. / Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda. In: AIDS and Behavior. 2016 ; pp. 1-6.
@article{c0fd77d921fb49f0bced5de3db8a9ebf,
title = "Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda",
abstract = "Little is known about associations between viral suppression, adherence, and duration of prior viral suppression in sub-Saharan Africa. Study participants were from the UARTO study in Mbarara, Uganda. We fit regression models to characterize relationships between average adherence, treatment interruptions, and rebound viremia (>400 copies/mL) following a previously undetectable result. Our goal was to understand the impact of prior viral suppression on these relationships. 396 participants contributed 2864 quarterly visits. Restricted to periods with average adherence <50 {\%}, each 10 {\%} increase in adherence reduced the odds of rebound viremia by 74 {\%} [adjusted odds ratio (AOR) = 0.26, P = 0.002] and 29 {\%} (AOR = 0.71, P = 0.057) during the first 12 months of suppression and beyond 12 months respectively, interaction term P = 0.018. Among periods with adherence ≥50 {\%}, the risk of rebound viremia decreased with increasing adherence during the first 12 months of viral suppression (AOR = 0.73 for each 10 {\%} increase, P = 0.001), but not thereafter (AOR = 1.09, P = 0.67), interaction term P = 0.027. In contrast, 72-h interruptions, were associated with increased rebound viremia during the first 12 months (AOR = 1.30, P = 0.009) and after (AOR = 1.39, P = 0.005), interaction term P = 0.69. Completing 12 months of viral suppression decreases the impact of average adherence, but not prolonged treatment interruptions, on risk of rebound viremia.",
keywords = "Adherence, ART, Suppression, Viremia",
author = "Nicholas Musinguzi and Mocello, {Rain A.} and Yap Boum and Hunt, {Peter W.} and Martin, {Jeffrey N.} and Haberer, {Jessica E.} and David Bangsberg and Siedner, {Mark J.}",
year = "2016",
month = "6",
day = "2",
doi = "10.1007/s10461-016-1447-1",
language = "English (US)",
pages = "1--6",
journal = "AIDS and Behavior",
issn = "1090-7165",
publisher = "Springer New York",

}

TY - JOUR

T1 - Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda

AU - Musinguzi, Nicholas

AU - Mocello, Rain A.

AU - Boum, Yap

AU - Hunt, Peter W.

AU - Martin, Jeffrey N.

AU - Haberer, Jessica E.

AU - Bangsberg, David

AU - Siedner, Mark J.

PY - 2016/6/2

Y1 - 2016/6/2

N2 - Little is known about associations between viral suppression, adherence, and duration of prior viral suppression in sub-Saharan Africa. Study participants were from the UARTO study in Mbarara, Uganda. We fit regression models to characterize relationships between average adherence, treatment interruptions, and rebound viremia (>400 copies/mL) following a previously undetectable result. Our goal was to understand the impact of prior viral suppression on these relationships. 396 participants contributed 2864 quarterly visits. Restricted to periods with average adherence <50 %, each 10 % increase in adherence reduced the odds of rebound viremia by 74 % [adjusted odds ratio (AOR) = 0.26, P = 0.002] and 29 % (AOR = 0.71, P = 0.057) during the first 12 months of suppression and beyond 12 months respectively, interaction term P = 0.018. Among periods with adherence ≥50 %, the risk of rebound viremia decreased with increasing adherence during the first 12 months of viral suppression (AOR = 0.73 for each 10 % increase, P = 0.001), but not thereafter (AOR = 1.09, P = 0.67), interaction term P = 0.027. In contrast, 72-h interruptions, were associated with increased rebound viremia during the first 12 months (AOR = 1.30, P = 0.009) and after (AOR = 1.39, P = 0.005), interaction term P = 0.69. Completing 12 months of viral suppression decreases the impact of average adherence, but not prolonged treatment interruptions, on risk of rebound viremia.

AB - Little is known about associations between viral suppression, adherence, and duration of prior viral suppression in sub-Saharan Africa. Study participants were from the UARTO study in Mbarara, Uganda. We fit regression models to characterize relationships between average adherence, treatment interruptions, and rebound viremia (>400 copies/mL) following a previously undetectable result. Our goal was to understand the impact of prior viral suppression on these relationships. 396 participants contributed 2864 quarterly visits. Restricted to periods with average adherence <50 %, each 10 % increase in adherence reduced the odds of rebound viremia by 74 % [adjusted odds ratio (AOR) = 0.26, P = 0.002] and 29 % (AOR = 0.71, P = 0.057) during the first 12 months of suppression and beyond 12 months respectively, interaction term P = 0.018. Among periods with adherence ≥50 %, the risk of rebound viremia decreased with increasing adherence during the first 12 months of viral suppression (AOR = 0.73 for each 10 % increase, P = 0.001), but not thereafter (AOR = 1.09, P = 0.67), interaction term P = 0.027. In contrast, 72-h interruptions, were associated with increased rebound viremia during the first 12 months (AOR = 1.30, P = 0.009) and after (AOR = 1.39, P = 0.005), interaction term P = 0.69. Completing 12 months of viral suppression decreases the impact of average adherence, but not prolonged treatment interruptions, on risk of rebound viremia.

KW - Adherence

KW - ART

KW - Suppression

KW - Viremia

UR - http://www.scopus.com/inward/record.url?scp=84973160459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973160459&partnerID=8YFLogxK

U2 - 10.1007/s10461-016-1447-1

DO - 10.1007/s10461-016-1447-1

M3 - Article

C2 - 27256394

AN - SCOPUS:84973160459

SP - 1

EP - 6

JO - AIDS and Behavior

JF - AIDS and Behavior

SN - 1090-7165

ER -